Diabetes self-management, an integral part of diabetes care, can be improved with the help of digital self-management tools such as apps, sensors, websites, and social media. The study objective was to reach a consensus on the criteria required to assess and recommend digital diabetes self-management tools targeting those with diabetes in Norway. Healthcare professionals working with diabetes care from all health regions in Norway were recruited to participate in a three-round Delphi study. In all rounds, the panellists rated criteria identified in a systematic review and interviews on a scale from 0-10, with the option to provide comments. On a scale of 0:not important to 10:extremely important, the highest rated criteria for assessing and recommending digital diabetes self-management tools were "Usability" and "Information quality", respectively. For assessing apps, "Security and privacy" was one of the lowest rated criteria. Having access to a list of criteria for assessing and recommending digital self-management tools can help diabetes care stakeholders to make informed choices in recommending and choosing suitable apps, websites, and social media for self-management. Future work on quality assessment of digital health tools should place emphasis on security and privacy compliance, to enable diabetes care stakeholders focus on other relevant criteria to recommend or choose and use such tools.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3233/SHTI210299 | DOI Listing |
JAMA Netw Open
January 2025
Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts.
Importance: Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.
Objective: To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes.
JAMA Intern Med
January 2025
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Importance: No large randomized clinical trial has directly compared empagliflozin with dapagliflozin, leaving their comparative effectiveness regarding kidney outcomes unknown.
Objective: To compare kidney outcomes between initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who were receiving antihyperglycemic treatment.
Design, Setting, And Participants: This target trial emulation used nationwide, population-based routinely collected Danish health care data to compare initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who received antihyperglycemic treatment between June 1, 2014, and October 31, 2020.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin, 150030, China.
Previous studies have shown that FGF-21 can ameliorate hyperglycemia and improve the level of oxidative stress in vivo in diabetic mice. The hypoglycemic effect is safe and lasting, but it takes a longer time to exert its effect. Insulin treatment of canine diabetes takes effect quickly; however, its action time is short, and it is prone to cause hypoglycemia.
View Article and Find Full Text PDFOrthopadie (Heidelb)
January 2025
Westdeutsches Diabetes- und Gesundheitszentrum, Verbund Katholischer Kliniken Düsseldorf, Hohensandweg 37, 40591, Düsseldorf, Deutschland.
Background: The prevalence of obesity has increased significantly in recent years and is a causal risk factor for the development of type 2 diabetes. Moreover, chronic degenerative joint diseases are also triggered by obesity.
Weight Loss: Both obesity-related secondary diseases-type 2 diabetes and chronic degenerative joint disease-can be prevented or at least delayed by lifestyle intervention aimed at weight reduction.
J Clin Endocrinol Metab
January 2025
Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ 08901, USA.
Context: Physical activity, exercise, or both are a staple of lifestyle management approaches both for type 1 diabetes mellitus (T1DM) and type 2 diabetes (T2DM). While the current literature supports both physical activity and exercise for improving glycemic control, reducing cardiovascular risk, maintaining proper weight, and enhancing overall well-being, the optimal prescription regimen remains debated.
Evidence Acquisition: We searched PubMed and Google Scholar databases for relevant studies on exercise, insulin sensitivity, and glycemic control in people with T1DM and T2DM.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!